OS Therapies (NYSE:OSTX) Stock Price Up 6.5% – Here’s What Happened

OS Therapies Inc (NYSE:OSTX) rose 6.5% during mid-day trading on Tuesday . The stock traded as high as $1.84 and last traded at $1.81. Approximately 199,223 shares traded hands during trading, a decline of 59% from the average daily volume of 483,725 shares. The stock had previously closed at $1.70.

Wall Street Analysts Forecast Growth

OSTX has been the subject of a number of research reports. Lake Street Capital assumed coverage on shares of OS Therapies in a report on Wednesday, April 2nd. They set a “buy” rating and a $19.00 target price for the company. D. Boral Capital restated a “buy” rating and issued a $20.00 price objective on shares of OS Therapies in a research note on Tuesday, April 22nd. Finally, Maxim Group lifted their target price on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research report on Thursday, January 16th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $18.00.

OS Therapies Stock Performance

The company’s 50-day simple moving average is $1.62 and its 200 day simple moving average is $2.39.

Insider Buying and Selling at OS Therapies

In other news, major shareholder Shalom Auerbach sold 50,012 shares of the stock in a transaction on Wednesday, April 9th. The shares were sold at an average price of $1.35, for a total value of $67,516.20. Following the sale, the insider now owns 2,756,199 shares of the company’s stock, valued at approximately $3,720,868.65. This represents a 1.78% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders have sold a total of 232,012 shares of company stock worth $515,516 over the last ninety days. Company insiders own 13.80% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently raised its position in OS Therapies stock. CM Management LLC raised its holdings in shares of OS Therapies Inc (NYSE:OSTX) by 120.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 110,044 shares of the company’s stock after purchasing an additional 60,044 shares during the quarter. CM Management LLC owned 0.51% of OS Therapies worth $471,000 at the end of the most recent reporting period.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.